Evidence map›Paper›PMID 36175994›Full record

ArticleBMC neurology2022

Case report of two affected siblings in a family with thiamine metabolism dysfunction syndrome 5: a rare, but treatable neurodegenerative disease.

Xiaoyan Li, Zhixin Huang, Yong Chen, Xiaolan Sun, Zhaoshi Yi, Jihua Xie, Xiongying Yu, Hui Chen, Jianmin Zhong

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaoyan Li *Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Zhixin Huang *Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Yong ChenDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Xiaolan SunDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Zhaoshi YiDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Jihua XieDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Xiongying YuDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Hui ChenDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China. chen19831102@sina.com.
Jianmin ZhongDepartment of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China. zhongjm@163.com.ORCID http://orcid.org/0000-0003-3203-6094
Jiangxi Provincial Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThiamine metabolism dysfunction syndrome 5 (THMD5) is a rare inherited metabolic disorder due to thiamine pyrophosphokinase 1(TPK1) deficiency, caused by mutations in TPK1. The core symptoms of the disease is acute or subacute onset encephalopathy, ataxia, muscle hypotonia, and regression of developmental milestones in early infancy, repeatedly triggered by acute infectious illness. However, we report two brothers of THMD5 with compound heterozygous for the mutations c.614-1G > A,c.224 T > A p.(Ile75Asn), but the prognosis is quite different if thiamine suppled. According to our current knowledge, the missense variant c.224 T > A p.(Ile75Asn) was not published previously. CASE PRESENTATION: Here, we describe two affected siblings in a Chinese family, after an uneventful pregnancy to non-consanguineous and healthy parents. The older brother presented with normal development during the first 6 months of life, but developed regression of developmental milestones after, accompanied with muscle hypotonia, and chronic encephalopathy, and died at 1 year and 6 months old. The younger brother presented with acute onset encephalopathy, ataxia, muscle hypotonia, repeatedly triggered by acute infectious illness. He was compound heterozygous for the mutations c.614-1G > A,c.224 T > A p.(Ile75Asn) identified by whole exome sequencing. He was diagnosed of THMD5 when he was 11 month. Oral supplementation of thiamine 100 mg/day, the symptoms gradually disappeared. At the age of 2 years and 4 months, he stoped thiamine, his symptoms returned and were once again relieved by oral supplementation of thiamine 100 mg/day.

conclusionsTHMD5 is a rare, but treatable neurodegenerative disease, the clinical phenotype ranges from mild to severe. Massive-dose of thiamine supplementation may ameliorate the course of TPK1 deficiency. When similar clinical cases appear, gene detection is particularly important, which is conducive to early diagnosis. Treatment with thiamine while awaiting the outcome of diagnostic tests may be a good choice.

Indexed as

Brain DiseasesNeurodegenerative DiseasesAtaxiaHumansMaleMuscle HypotoniaMutationSiblingsThiamineThiamin PyrophosphokinaseThiamineThiamin PyrophosphokinaseCase reportThiamineThiamine metabolism dysfunction syndrome 5TPK1

Identifiers

PMID36175994
PMCPMC9520874
OpenAlexW4298004957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.